Table 1 Baseline characteristics of study population
Total (N = 573) | Recent cocaine/crack use (N = 211) | Previously used cocaine/crack; not recent (N = 290) | Never used cocaine/crack (N = 72) | |
|---|---|---|---|---|
Follow-up time (years)a | 2.3 (1.0, 4.1) | 2.1 (1.0, 3.9) | 2.4 (1.1, 4.5) | 2.0 (0.8, 4.4) |
Age (years) | 44 (38, 49) | 43 (38, 49) | 44 (38, 48) | 47 (40, 53) |
Female | 173 (30%) | 69 (33%) | 81 (28%) | 23 (32%) |
Aboriginal | 86 (15%) | 53 (25%) | 31 (11%) | 2 (3%) |
Time since HIV diagnosis (years) | 10 (5, 16) | 10 (5, 14) | 10 (6, 16) | 13 (5, 20) |
Duration HCV infection (years) | 18 (10, 25) | 19 (12, 26) | 18 (11, 25) | 10 (4, 20) |
CD4 cell count (cells/μL) | 389 (253, 550) | 360 (220, 528) | 390 (260, 550) | 439 (300, 601) |
HIV RNA load ≤ 50 copies/mL | 340 (59%) | 117 (55%) | 175 (60%) | 48 (67%) |
Time since first start of ART (years) | 6 (2, 11) | 6 (2, 10) | 6 (3, 11) | 9 (2, 12) |
cART regimen | 453 (79%) | 164 (78%) | 227 (78%) | 62 (86%) |
Prior AIDS diagnosis | 162 (28%) | 65 (31%) | 77 (27%) | 20 (28%) |
APRI | 0.5 (0.4, 0.8) | 0.5 (0.4, 0.7) | 0.6 (0.4, 0.8) | 0.6 (0.4, 1.0) |
HCV RNA (log10 UI/mL)b | 6.2 (5.4, 6.7) | 6.1 (5.1, 6.6) | 6.2 (5.5, 6.8) | 6.2 (5.6, 6.7) |
HCV treatment naïve | 512 (89%) | 197 (93%) | 258 (89%) | 57 (79%) |
Alcohol abusec | 83 (14%) | 41 (19%) | 37 (13%) | 5 (7%) |